By Drug companies must make fundamental changes to their core business to address R&D gaps and access to existing medicines for women’s sexual and reproductive health in lower-income countries, global health equity advocates urge.
Drug companies must address ‘chronic neglect’ of women: Report
AI background business technology, digital transformation
Comments